Last reviewed · How we verify
NCT04421469
Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC
Phase 2 trial testing Triprilimab(JS001) in Nasopharyngeal Carcinoma in 39 participants. Status unknown.
15 April 2023
Quick facts
| Lead sponsor | Fujian Cancer Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 39 |
| Start date | 15 June 2020 |
| Primary completion | 15 April 2023 |
| Estimated completion | 15 June 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Triprilimab(JS001) — full drug profile →
Conditions studied
- Nasopharyngeal Carcinoma — all drugs for Nasopharyngeal Carcinoma →
Sponsor
Fujian Cancer Hospital
Who can join
Adults 18 to 70, any sex, with Nasopharyngeal Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a randomized, phase II, prospective, multicenter clinical trial to evaluate the efficacy and tolerability of JS001 and chemotherapy combined with local treatment in patients with multiple metastatic nasopharyngeal carcinoma.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes.
Liu H, Tang L, Li Y, Xie W, et al · · 2024 · cited 85× · PMID 38254110 · DOI 10.1186/s12943-023-01928-2 -
Current status and advances of immunotherapy in nasopharyngeal carcinoma.
Xu JY, Wei XL, Wang YQ, Wang FH. · · 2022 · cited 62× · PMID 35547095 · DOI 10.1177/17588359221096214 -
Nasopharyngeal Carcinoma and Its Microenvironment: Past, Current, and Future Perspectives.
Su ZY, Siak PY, Leong CO, Cheah SC. · · 2022 · cited 32× · PMID 35311066 · DOI 10.3389/fonc.2022.840467 -
Revealing the crosstalk between nasopharyngeal carcinoma and immune cells in the tumor microenvironment.
Jiang J, Ying H. · · 2022 · cited 29× · PMID 35964134 · DOI 10.1186/s13046-022-02457-4 -
Locoregional radiotherapy improves survival outcomes in de novo metastatic nasopharyngeal carcinoma treated with chemoimmunotherapy.
Hu YJ, Lu TZ, Zhang H, Fang M, et al · · 2023 · cited 13× · PMID 37660406 · DOI 10.1016/j.esmoop.2023.101629 -
Anatomic prognostic factors and their potential roles in refining M1 classification for de novo metastatic nasopharyngeal carcinoma.
Lu TZ, Zeng FJ, Hu YJ, Fang M, et al · · 2023 · cited 8× · PMID 38073447 · DOI 10.1002/cam4.6816 -
Development and validation of a machine learning model for predicting 3-year overall survival in metastatic nasopharyngeal carcinoma: a SEER database and web visualization study.
Qiu L, Fei Y, Zhu Y, Shi K, et al · · 2025 · PMID 41234899 · DOI 10.21037/tcr-2025-977
Verify or expand the search:
- PubMed search for NCT04421469
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Triprilimab(JS001)
Trials testing the same drug.
- NCT04890522 — An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC · Phase 2, PHASE3 · not yet recruiting
Other recruiting trials for Nasopharyngeal Carcinoma
Currently open trials in the same condition.
- NCT06059261 — Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. · Phase 2 · recruiting
- NCT07328854 — 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma · Phase 3 · recruiting
- NCT06912711 — TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma · Phase 2 · recruiting
- NCT07000643 — Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma · Phase 3 · recruiting
- NCT06682442 — Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma · NA · recruiting
Other Fujian Cancer Hospital trials
Trials by the same sponsor.
- NCT07470840 — SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma · Phase 2 · not yet recruiting
- NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
- NCT07492654 — Clinical Study on the Prevention and Treatment of Radiation Vaginitis With Triethanolamine Cream · Phase 4 · not yet recruiting
- NCT07399158 — CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Respons · not yet recruiting
- NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04421469 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fujian Cancer Hospital
- Last refreshed: 9 June 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04421469.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing